Clinical Trials Directory

Trials / Completed

CompletedNCT03765359

Metformin Use to Improve Pregnancy Outcome in Women With Type 1 Diabetes.

Metformin Use to Improve Pregnancy Outcome in Women With Type 1 Diabetes. A Randomized Double-blind Placebo-controlled Multicenter Study.

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
101 (actual)
Sponsor
Tampere University Hospital · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

The study investigates whether additional metformin medication in combination with regular insulin treatment will decrease the need of insulin for women with diabetes mellitus type 1 during pregnancy.

Detailed description

Insulin resistance during pregnancy of diabetes mellitus type 1 patients (DM1) increases the need for insulin and makes it more difficult to maintain normoglycemia. Fetal exposure to hyperglycemia induces macrosomia which increases fetal and neonatal morbidity and mortality. Further more obesity and excess weight gain during pregnancy enhances insulin resistance and it's an independent risk factor for fetal macrosomia. Metformin is a medical treatment for type 2 diabetes (DM2) where consequential pathophysiology includes insulin resistance. It reduces hepatic glucose production and enhances the use of glucose in muscles relieving insulin resistance. Metformin has also found to inhibit weight gain effectively. Metformin has approved to be safe and effective in patients with gestational diabetes (GDM). It has found to reduce weight gain and improve postprandial blood glucose levels during pregnancy and reduce neonatal birth trauma in GDM. However, there are no previous studies about the use of metformin in pregnant women with DM1. Two hundred women with DM1 will be randomized to get placebo or metformin in addition to regular insulin treatment. The sample size has been estimated to demonstrate the difference of 15 % in the need to increase insulin dosages during the pregnancy between the study groups.

Conditions

Interventions

TypeNameDescription
DRUGmetforminhydrochloridemetformin 500 mg tablets and insulin
DRUGPlacebo Oral TabletPlacebo tablets mimic metformin 500 mg tablets and insulin

Timeline

Start date
2019-08-05
Primary completion
2022-12-19
Completion
2022-12-19
First posted
2018-12-05
Last updated
2023-06-07

Locations

5 sites across 1 country: Finland

Source: ClinicalTrials.gov record NCT03765359. Inclusion in this directory is not an endorsement.